Lymphomas Non-Hodgkin's B-CellPhase 1INVISENCT06539338
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
A Phase 1 study testing INT2104 in people with Lymphomas Non-Hodgkin's B-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma, run by Kite, A Gilead Company at 3 sites in 2 countries.
Trial summary
The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies. Preliminary efficacy information may also be obtained. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- What is being tested?
- INT2104
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- 3 sitesin 2 countries
- Study dates
- 20 Sep 2024to Oct 2026
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosed with relapsed/refractory (R/R) B-NHL (Burkitt's lymphoma are eligible for Part B only) confirmed by histology or flow cytometry Note: Bone Marrow involvement is allowed
- B-NHL must have CD20 antigen positive tumour confirmed from a tumour biopsy taken at screening
- Measurable disease at the time of enrolment
- Progression after at least 2 lines of systemic therapy
- Has not received more than one prior marketed CAR-T cell therapy (including tandem or bispecific CAR-T) or other genetically modified T-cell therapy.
- Sex and Contraceptive/Barrier Requirements consistent with local regulations for clinical trials Females: must have negative serum pregnancy test at screening and on Day -1 prior to INT2104 infusion Both sexes: must agree to use highly effective methods, including a barrier method after INT2104 infusion
Show all 16Show fewer
- Haematological criteria:
- Absolute lymphocyte count (ALC) ≥300/µL
- Platelet count ≥50,000/mL
- Absolute neutrophil count (ANC) ≥500/µL
- Eastern Cooperative Oncology Group (ECOG) score of 0 or 1
- Adequate renal, cardiac, hepatic, and lung function
- Diagnosed with relapsed/refractory B-ALL, and with exceptions as detailed in exclusion criteria. Participants with Philadelphia chromosome positive (Ph+) B-ALL disease are eligible.
- B-ALL participants must have CD20 antigen positive leukaemia
- Measurable disease at the time of enrolment
- Participants with Burkitt's lymphoma are eligible for Part B only
Who cannot join
- Central Nervous System (CNS)-only B-cell malignancy, or B-cell malignancy with R/R secondary CNS involvement.
- Diagnosis or history of chronic lymphocytic leukaemia (CLL) (including large cell [Richter] transformation of CLL) or small lymphocytic lymphoma (SLL)
- Diagnosis or history of cutaneous lymphoma
- History of another primary malignancy that has not been in remission for at least 3 years before signing informed consent (except for: non-melanoma skin cancer, low grade prostate cancer or carcinoma in situ (e.g., cervix, bladder, breast))
- Acute or chronic graft-versus-host disease
- Participant has received donor lymphocyte infusion within 6 weeks prior to INT2104 infusion
Show all 18Show fewer
- History of autoimmune disease requiring systemic immunosuppression/ systemic disease modifying agents within 2 years before enrolment
- History or presence of CNS disorder
- History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months before signing informed consent
- Participants has active syphilis, cytomegalovirus (CMV), acute or chronic active hepatitis B, or untreated hepatitis C.
- Participant is Human immunodeficiency virus (HIV) positive.
- Any medical condition likely to interfere with assessment of safety or efficacy of the study treatment
- A vaccine within 4 weeks prior to INT2104 infusion
- Intolerance or severe hypersensitivity reaction to any excipients of the INT2104 product.
- An active fungal, bacterial, viral, or other infection that is uncontrolled or requires antimicrobials at the time of INT2104 infusion.
- Participant is pregnant or nursing.
- In the investigator's judgment, the participant is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
- Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Trial locations and contacts
3 sites in 2 countries.
3 sites in 2 countries
Australia2 sites
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000
Westmead Hospital
Westmead, New South Wales, 2145
About this study
Official title: A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusion in Female and Male Participants Aged 18 Years of Age and Older With Refractory/Relapsing B-Cell Malignancies
The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies. Preliminary efficacy information may also be obtained.
INT2104 is a gene therapy delivering a transgene for a chimeric antigen receptor (CAR) specific for CD20 (CAR20). The lentiviral vector is designed to generate CAR T and CAR Natural Killer (NK) cells inside the body following intravenous (IV) administration.
Study details include the following:
- The study duration will be 5 years
- The treatment duration will be a one-time intravenous (IV) infusion of INT2104
Read the detailed description
This is a non-randomized, open label, multi-site, Phase 1 First in Human (FIH) study split into two parts. The first part (Part A) is a dose escalation and the second part (Part B) will be to confirm the dose.
The aim of the study is to collect data to assess whether the study product, INT2104, is safe and tolerable, to understand how well INT2104 works in the human body and to select the dose to take into a Phase 2 study.
All participants will receive one intravenous (IV) infusion of INT2104.
Each participant in the study will follow the same study treatment schedule and will proceed through the following study periods:
- Screening Period: participant will be assessed for eligibility
- Study Day 1: participants who meet all eligibility criteria will receive INT2104 by a one-time infusion
- Post-treatment Assessment Period: participants will be followed regularly with clinic visits after they receive INT2104
- Being tested
- INT2104
- Keywords
- Gene Therapy
- Medical subject headings
- Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
INT2104Genetic
INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
| Study group | Role | What they receive |
|---|---|---|
| INT2104 Dose Level 1 | Experimental | Single IV administration of INT2104 Receives: Genetic: INT2104 |
| INT2104 Dose Level 2 | Experimental | Single IV administration of INT2104 Receives: Genetic: INT2104 |
| INT2104 Dose Level 3 | Experimental | Single IV administration of INT2104 Receives: Genetic: INT2104 |
| INT2104 Dose Level 4 | Experimental | Single IV administration of INT2104 Receives: Genetic: INT2104 |
| INT2104 Recommended Dose | Experimental | Single IV administration of INT2104 Receives: Genetic: INT2104 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Treatment-emergent Adverse Events
Number of Participants With Adverse Events as Assessed by CTCAE v5.0
Measured: Up to 5 years
Number of Participants With Abnormal Clinical Laboratory Values and Physical Examination Results
Number of Participants With abnormal clinical laboratory values as Assessed by CTCAE v5.0
Measured: Baseline, up to Day 29
Number of Participants Experiencing Cytokine Release Syndrome (CRS)
Number of participants experiencing Cytokine Release Syndrome (CRS)
Measured: Baseline, up to Day 29
Number of Participants Experiencing Immune Effector Cell Neurotoxicity (ICANS)
Number of participants experiencing Immune Effector Cell Neurotoxicity (ICANS)
Measured: 28 Days
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Number of participants experiencing dose-limiting toxicities (DLTs)
Measured: 28 Days
Secondary outcomes (25)
Levels of Vector Ribonucleic Acid (RNA) Genomes in Blood Over Time
Measured: Baseline, up to Day 29
Levels of Transgene Deoxyribonucleic Acid (DNA) Copies in Blood Over Time
Measured: Baseline, up to Day 29
Levels of CD20-targeting Chimeric Antigen Receptor (CAR20) Positive T Cells in Blood Over Time
Measured: Baseline, up to Day 29
Levels of Natural Killer (NK) Cells in Blood Over Time
Measured: Baseline, up to Day 29
Number of Participants with CAR20-positive Cells in Accessible Tumour Tissue Over Time
Measured: Baseline, up to Day 29
Change in the Levels of Lymphocyte Subsets Including B-cell Counts Over Time
Measured: Baseline, up to Day 29
Objective Response Rate (ORR) as Determined by Investigator Assessment
Measured: Day 90
Objective Response Rate (ORR) as Determined by Investigator Assessment
Measured: Year 1
Objective Response Rate (ORR) as Determined by Investigator Assessment
Measured: Year 2
Objective Response Rate (ORR) as Determined by Investigator Assessment
Measured: Year 5
Complete Response (CR) Rate as Determined by Investigator Assessment
Measured: Day 90
Complete Response (CR) Rate as Determined by Investigator Assessment
Measured: Year 1
Complete Response (CR) Rate as Determined by Investigator Assessment
Measured: Year 2
Complete Response (CR) Rate as Determined by Investigator Assessment
Measured: Year 5
Duration of response (DOR) as Determined by Investigator Assessment
Measured: Up to 5 years
Progression Free Survival (PFS) as Determined by Investigator Assessment
Measured: Up to 5 years
Overall Survival (OS) as Determined by Investigator Assessment
Measured: Up to 5 years
Number of Participants with Cytokine Release Syndrome (CRS)
Measured: Up to 5 years
Number of Participants with Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
Measured: Up to 5 years
Duration of Cytokine Release Syndrome (CRS)
Measured: Up to 5 years
Duration of ICANS
Measured: Up to 5 years
Number of Participants with Vector-derived Replication Competent Lentivirus (RCL) Through Year 5
Measured: Up to 5 years
Assessment of Humoral Immunity: Number of Participants with Anti-CAR and Anti-vector Antibodies Over Time
Measured: Up to 5 years
Assessment of Cellular Immunity: Number of Participants with Changes in T-cell Enzyme-Linked Immunospot Assay (ELISPOT) and Cytokine Profiles Over Time
Measured: Up to 5 years
Assessment of Vector Shedding: Number of Participants with Vector Shedding in Saliva, Faeces, and Urine Over Time
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2024
- Study start20 Sep 2024
- Primary completionOct 2026 (estimated)
- Study completionOct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lymphomas Non-Hodgkin's B-CellStudies of the same condition, open and under way.
- More trials run by Kite, A Gilead CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 10 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kite, A Gilead Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kite Study Director, Study director, Kite, A Gilead Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06539338
- Sponsor's protocol ID
- INT2104-101
- Other IDs
- 2023-509132-26-00, U1111-1303-9462, 2023
- Acronym
- INVISE
- Status last verified
- Sep 2026
- First submitted
- 19 Jun 2024
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusion in Female and Male Participants Aged 18 Years of Age and Older With Refractory/Relapsing B-Cell Malignancies
- ClinicalTrials.gov ID
- NCT06539338
- Acronym / sponsor ID
- INVISE / INT2104-101
- Keywords
- Gene Therapy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 10 participants (actual)
- Lead sponsor
- Kite, A Gilead CompanyIndustry (pharma, biotech, devices)
- Study start
- 20 Sep 2024 (actual)
- Primary completion
- Oct 2026 (estimated)
- Study completion
- Oct 2026 (estimated)
- First posted
- 6 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies. Preliminary efficacy information may also be obtained.
INT2104 is a gene therapy delivering a transgene for a chimeric antigen receptor (CAR) specific for CD20 (CAR20). The lentiviral vector is designed to generate CAR T and CAR Natural Killer (NK) cells inside the body following intravenous (IV) administration.
Study details include the following:
- The study duration will be 5 years
- The treatment duration will be a one-time intravenous (IV) infusion of INT2104
Detailed description
This is a non-randomized, open label, multi-site, Phase 1 First in Human (FIH) study split into two parts. The first part (Part A) is a dose escalation and the second part (Part B) will be to confirm the dose.
The aim of the study is to collect data to assess whether the study product, INT2104, is safe and tolerable, to understand how well INT2104 works in the human body and to select the dose to take into a Phase 2 study.
All participants will receive one intravenous (IV) infusion of INT2104.
Each participant in the study will follow the same study treatment schedule and will proceed through the following study periods:
- Screening Period: participant will be assessed for eligibility
- Study Day 1: participants who meet all eligibility criteria will receive INT2104 by a one-time infusion
- Post-treatment Assessment Period: participants will be followed regularly with clinic visits after they receive INT2104
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| INT2104 Dose Level 1 | Experimental | Genetic: INT2104Single IV administration of INT2104 |
| INT2104 Dose Level 2 | Experimental | Genetic: INT2104Single IV administration of INT2104 |
| INT2104 Dose Level 3 | Experimental | Genetic: INT2104Single IV administration of INT2104 |
| INT2104 Dose Level 4 | Experimental | Genetic: INT2104Single IV administration of INT2104 |
| INT2104 Recommended Dose | Experimental | Genetic: INT2104Single IV administration of INT2104 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Diagnosed with relapsed/refractory (R/R) B-NHL (Burkitt's lymphoma are eligible for Part B only) confirmed by histology or flow cytometry Note: Bone Marrow involvement is allowed
- B-NHL must have CD20 antigen positive tumour confirmed from a tumour biopsy taken at screening
- Measurable disease at the time of enrolment
- Progression after at least 2 lines of systemic therapy
- Has not received more than one prior marketed CAR-T cell therapy (including tandem or bispecific CAR-T) or other genetically modified T-cell therapy.
Key exclusion criteria (18 listed)
- Central Nervous System (CNS)-only B-cell malignancy, or B-cell malignancy with R/R secondary CNS involvement.
- Diagnosis or history of chronic lymphocytic leukaemia (CLL) (including large cell [Richter] transformation of CLL) or small lymphocytic lymphoma (SLL)
- Diagnosis or history of cutaneous lymphoma
- History of another primary malignancy that has not been in remission for at least 3 years before signing informed consent (except for: non-melanoma skin cancer, low grade prostate cancer or carcinoma in situ (e.g., cervix, bladder, breast))
- Acute or chronic graft-versus-host disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| INT2104INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20) | Genetic | INT2104 Dose Level 1, INT2104 Dose Level 2, INT2104 Dose Level 3, INT2104 Dose Level 4, INT2104 Recommended Dose |
Primary outcome
Number of Participants With Treatment-emergent Adverse Events
Time frame: Up to 5 years
Number of Participants With Adverse Events as Assessed by CTCAE v5.0
Number of Participants With Abnormal Clinical Laboratory Values and Physical Examination Results
Time frame: Baseline, up to Day 29
Number of Participants With abnormal clinical laboratory values as Assessed by CTCAE v5.0
Number of Participants Experiencing Cytokine Release Syndrome (CRS)
Time frame: Baseline, up to Day 29
Number of participants experiencing Cytokine Release Syndrome (CRS)
Number of Participants Experiencing Immune Effector Cell Neurotoxicity (ICANS)
Time frame: 28 Days
Number of participants experiencing Immune Effector Cell Neurotoxicity (ICANS)
Number of Participants Experiencing dose-limiting toxicities (DLTs)
Time frame: 28 Days
Number of participants experiencing dose-limiting toxicities (DLTs)
25 secondary outcomes
Levels of Vector Ribonucleic Acid (RNA) Genomes in Blood Over Time
Time frame: Baseline, up to Day 29
Levels of Transgene Deoxyribonucleic Acid (DNA) Copies in Blood Over Time
Time frame: Baseline, up to Day 29
Levels of CD20-targeting Chimeric Antigen Receptor (CAR20) Positive T Cells in Blood Over Time
Time frame: Baseline, up to Day 29
Levels of Natural Killer (NK) Cells in Blood Over Time
Time frame: Baseline, up to Day 29
Number of Participants with CAR20-positive Cells in Accessible Tumour Tissue Over Time
Time frame: Baseline, up to Day 29
Change in the Levels of Lymphocyte Subsets Including B-cell Counts Over Time
Time frame: Baseline, up to Day 29
Objective Response Rate (ORR) as Determined by Investigator Assessment
Time frame: Day 90
Objective Response Rate (ORR) as Determined by Investigator Assessment
Time frame: Year 1
Objective Response Rate (ORR) as Determined by Investigator Assessment
Time frame: Year 2
Objective Response Rate (ORR) as Determined by Investigator Assessment
Time frame: Year 5
Complete Response (CR) Rate as Determined by Investigator Assessment
Time frame: Day 90
Complete Response (CR) Rate as Determined by Investigator Assessment
Time frame: Year 1
Complete Response (CR) Rate as Determined by Investigator Assessment
Time frame: Year 2
Complete Response (CR) Rate as Determined by Investigator Assessment
Time frame: Year 5
Duration of response (DOR) as Determined by Investigator Assessment
Time frame: Up to 5 years
Progression Free Survival (PFS) as Determined by Investigator Assessment
Time frame: Up to 5 years
Overall Survival (OS) as Determined by Investigator Assessment
Time frame: Up to 5 years
Number of Participants with Cytokine Release Syndrome (CRS)
Time frame: Up to 5 years
Number of Participants with Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)
Time frame: Up to 5 years
Duration of Cytokine Release Syndrome (CRS)
Time frame: Up to 5 years
Duration of ICANS
Time frame: Up to 5 years
Number of Participants with Vector-derived Replication Competent Lentivirus (RCL) Through Year 5
Time frame: Up to 5 years
Assessment of Humoral Immunity: Number of Participants with Anti-CAR and Anti-vector Antibodies Over Time
Time frame: Up to 5 years
Assessment of Cellular Immunity: Number of Participants with Changes in T-cell Enzyme-Linked Immunospot Assay (ELISPOT) and Cytokine Profiles Over Time
Time frame: Up to 5 years
Assessment of Vector Shedding: Number of Participants with Vector Shedding in Saliva, Faeces, and Urine Over Time
Time frame: Up to 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Gilead Clinical Trials WebsiteLink provided by the sponsor.
Related trials for Lymphomas Non-Hodgkin's B-Cell
Active, not recruitingPhase 1/2
Study of Oral MRT-2359 in Selected Cancer Patients
NSCLC, SCLC
Active, not recruitingPhase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
B Cell ALL, B-Cell Lymphoma
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Not yet recruitingPhase 2
The CARDIOPROTECT Trial
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
RecruitingPhase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kite Study Director study director
Kite, A Gilead Company
3 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing INT2104 in people with Lymphomas Non-Hodgkin's B-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma, run by Kite, A Gilead Company at 3 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in Australia, Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Treatment-emergent Adverse Events (time frame: Up to 5 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.